Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Trigeminal Neuralgia

医学 可视模拟标度 随机对照试验 三叉神经痛 科克伦图书馆 置信区间 荟萃分析 麻醉 肉毒毒素 子群分析 内科学
作者
Xinyu Hu,Yun Xia,Jingwen Li,Xinyi Wang,Hanshu Liu,Jichuan Hu,Juan Bi,Jing Wu,Tao Wang,Zhicheng Lin,Nian Xiong
出处
期刊:The Clinical Journal of Pain [Lippincott Williams & Wilkins]
卷期号:40 (6): 383-392 被引量:1
标识
DOI:10.1097/ajp.0000000000001207
摘要

Objective: Pain management in patients with TN is challenging, as facial pain often does not respond well to conventional therapies. Botulinum toxin type A (BTX-A) has been suggested as a potential treatment option, but there is limited evidence regarding its long-term efficacy. This review aimed to analyze the current data for the use of in the treatment of trigeminal neuralgia (TN) and highlight the evidence for its efficacy and safety. Methods: A comprehensive search was conducted in various databases (PubMed, Scopus, Embase, ClinicalTrials, and Cochrane Library) to identify clinical studies evaluating the use of BTX-A in TN until October 2023. Randomized controlled trials (RCTs), single-arm studies, and stratified studies were included in the analysis. The mean difference (MD), effect size (ES), and 95% confidence interval (CI) were estimated for visual analogue scale (VAS) scores, pain episode frequency, and the proportion of responders. Results: The analysis included 23 studies, including 4 RCTs, 14 single-arm studies, and 5 stratified studies. In the RCTs, BTX-A was found to significantly reduce mean VAS scores compared with baseline (ES: −4.05; 95% CI: −6.13, −1.97; P =0.002). In 19 non-RCTs, the pooled single-arm analysis revealed that BTX-A decreased VAS scores (ES: -5.19, 95% CI: −6.05, −4.33, P <0.001) and pain attack frequency (ES: −17.85, 95% CI: −23.36, −12.34, P <0.001) from baseline to the end of follow-up. The overall proportion of responders to BTX-A treatment was also significant (95% CI: 0.653, 0.761, P =0.003). Discussion: Current evidence indicates that BTX-A injection is an effective and safe option for patients with refractory TN or not responding to medical or surgical management. However, more high-quality studies are needed to further confirm its efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Liang完成签到,获得积分10
1秒前
TC发布了新的文献求助10
2秒前
传奇3应助枕星采纳,获得10
2秒前
凡凡发布了新的文献求助10
3秒前
免疫与代谢研究完成签到,获得积分10
4秒前
jiajiajai发布了新的文献求助10
5秒前
西早07完成签到,获得积分10
5秒前
Meng完成签到,获得积分10
6秒前
Neo完成签到,获得积分10
7秒前
keyaner完成签到,获得积分10
9秒前
童林艳完成签到,获得积分10
9秒前
ECHO完成签到,获得积分10
11秒前
Lucas应助Fang Xianxin采纳,获得10
12秒前
xiaoyao完成签到,获得积分10
13秒前
asss完成签到,获得积分10
13秒前
Y123发布了新的文献求助30
14秒前
LOVER完成签到 ,获得积分10
15秒前
松松完成签到 ,获得积分10
15秒前
17秒前
nater4ver完成签到,获得积分10
18秒前
UU发布了新的文献求助10
20秒前
超帅鸭子完成签到,获得积分10
20秒前
LXZ完成签到,获得积分10
20秒前
依惜完成签到,获得积分10
20秒前
zhaokunfeng关注了科研通微信公众号
20秒前
赫青亦完成签到 ,获得积分10
20秒前
exy完成签到,获得积分10
21秒前
zhaohu47完成签到,获得积分10
22秒前
超帅鸭子发布了新的文献求助10
22秒前
每每反完成签到,获得积分10
24秒前
凡凡完成签到 ,获得积分10
25秒前
26秒前
呆鹅喵喵完成签到,获得积分10
26秒前
忧心的洙完成签到,获得积分10
27秒前
123完成签到,获得积分10
27秒前
青青草完成签到,获得积分10
29秒前
Fang Xianxin完成签到,获得积分20
29秒前
yue发布了新的文献求助10
29秒前
小甘看世界完成签到,获得积分0
31秒前
量子星尘发布了新的文献求助10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029